Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Claire N Harrison, Professor, Aaron T. Gerds, MD MS, Jean-Jacques Kiladjian, MD PhD, Konstanze Döhner, Sarah A Buckley, MD, Jennifer A. Smith, PhD, Adam R Craig, MD PhD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4175.

https://doi.org/10.1182/blood-2019-129245

Published: 2019

Journal Articles

Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Blood (2016) 128 (22): 903.

https://doi.org/10.1182/blood.V128.22.903.903

Published: 2016

Journal Articles

Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study

Blood (2015) 126 (23): 2560.

https://doi.org/10.1182/blood.V126.23.2560.2560

Published: 2015

Journal Articles

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Naval Daver, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, Naveen Pemmaraju, MD, Kenneth Vaughan, Sherry Pierce, BSN, BA, Marina Konopleva, MD PhD, Tapan Kadia, MD, Courtney DiNardo, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Adam R Craig, MD PhD, Farhad Ravandi, MD

Blood (2015) 126 (23): 461.

https://doi.org/10.1182/blood.V126.23.461.461

Published: 2015

Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Blood (2014) 124 (21): LBA-6.

https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6

Published: 2014

Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, Digumarti Raghunadharao, MD, Purvish Parikh, MD, Meir Wetzler, MD, Jeffrey H. Lipton, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Hagop M. Kantarjian, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 861.

https://doi.org/10.1182/blood.V114.22.861.861

Published: 2009

Journal Articles

Downregulation of the Common Cytokine Receptor Subunit Beta c by Omacetaxine in CML: A Potential Molecular Mechanism to Overcome Cytokine-Mediated Resistance against BCR-ABL-Inhibitors.

Thomas Klag, MD, Nicolai Härtel, MD, Thomas Schenk, MD, Adam R Craig, MD, PhD, Andreas Hochhaus, MD, Paul La Rosee, MD

Blood (2009) 114 (22): 3256.

https://doi.org/10.1182/blood.V114.22.3256.3256

Published: 2009

Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, H. Jean Khoury, MD, FACP, Franck Emmanuel Nicolini, MD, PhD, Selim Corm, Jeffrey H. Lipton, MD,PhD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Hagop Kantarjian, MD

Blood (2009) 114 (22): 644.

https://doi.org/10.1182/blood.V114.22.644.644

Published: 2009

Journal Articles

Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.

Jorge Cortes, MD, H. Jean Khoury, MD, Sélim Corm, MD, Franck E Nicolini, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, MD, Eric Humphriss, Hagop Kantarjian

Blood (2008) 112 (11): 3239.

https://doi.org/10.1182/blood.V112.11.3239.3239

Published: 2008

Journal Articles

A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors.

Hagop M. Kantarjian, MD, Jorge Cortes, MD, Philipp le Coutre, MD, Arnon Nagler, MD, Javier Pinilla, MD, Andreas Hochhaus, MD, Dan Jones, MD, PhD, Adam R. Craig, MD, PhD, Eileen Carroll, Oliver G. Ottmann, MD

Blood (2007) 110 (11): 469.

https://doi.org/10.1182/blood.V110.11.469.469

Published: 2007

Journal Articles

The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Immatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients.

Wenjing Tao, PhD, Tong Sun, MS, Adam R. Craig, MD, PhD, Jorge E. Cortes, MD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD, Premkumar E. Reddy, PhD, Hagop M. Kantarjian, MD, Ralph B. Arlinghaus, PhD

Blood (2006) 108 (11): 2179.

https://doi.org/10.1182/blood.V108.11.2179.2179

Published: 2006

NARROW

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

Downregulation of the Common Cytokine Receptor Subunit Beta c by Omacetaxine in CML: A Potential Molecular Mechanism to Overcome Cytokine-Mediated Resistance against BCR-ABL-Inhibitors.

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.

A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors.

The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Immatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only